Form 4: Sage Therapeutics Director Jessica Federer Granted Stock Options

Director Jessica Federer of Sage Therapeutics was granted stock options under the company's 2024 Equity Incentive Plan.

Summary

• Jessica Federer, a director at Sage Therapeutics, was granted stock options on June 10, 2024.
• The options, which are a right to buy 12,500 shares of common stock, were granted under the Sage Therapeutics, Inc. 2024 Equity Incentive Plan.
• The exercise price of the options is $10.90 per share.
• The options will vest in full on the earlier of June 10, 2025, or the day immediately prior to the 2025 Annual Meeting of Sage's stockholders, contingent upon continued service as a director.
• Federer also has granted power of attorney to Anne Marie Cook, Kimi Iguchi, Brandon Marsh, and Stuart Falber to file necessary forms with the SEC.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Future Outlook

The director's continued service is incentivized by the vesting schedule of the stock options.

Industry Context

Stock option grants are a common form of compensation for directors in publicly traded companies, aligning their interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's performance.
• The director is incentivized to contribute to the company's success to increase the value of the stock options.

Key Dates